Clinical trial
Diffuse Fibrotic Lung Disease
NCT00000596 · National Heart, Lung, and Blood Institute (NHLBI), NIH · Completed
Key facts
| NCT number | NCT00000596 |
|---|---|
| Title | Diffuse Fibrotic Lung Disease |
| Lead sponsor | National Heart, Lung, and Blood Institute (NHLBI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Diseases, Pulmonary Fibrosis, Sarcoidosis |
| Intervention type | Drug |
| Interventions | prednisone, cyclophosphamide, dapsone |
| Start date | Jun 1, 1978 |
| Completion | Jan 1, 1983 |
| First posted | Oct 28, 1999 |
| Last update posted | Nov 26, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: